Corporate GovernanceJul 29, 2026, 05:11 PM
Kura Oncology Modifies Executive Severance Provisions
AI Summary
Kura Oncology, Inc. has modified the severance provisions in the employment agreements for its Chairman, President, and CEO, Dr. Troy E. Wilson, and for its Chief Commercial Officer, Brian Powl, and Chief Operating Officer, Kathleen Ford. The updated agreements detail severance packages for termination without cause or resignation for good reason, with enhanced benefits in the event of a corporate transaction. These modifications clarify the terms of executive compensation and protection.
Key Highlights
- Kura Oncology updated executive employment agreements for CEO, CCO, and COO.
- CEO Dr. Wilson's severance: 12 months base salary (standard); 24 months base salary + 200% target bonus (change of control).
- CEO Dr. Wilson's severance includes 12-24 months COBRA and full equity vesting upon change of control.
- CCO Brian Powl and COO Kathleen Ford's severance: 12 months base salary (standard).
- CCO/COO severance: 18 months base salary + 150% target bonus (change of control).
- CCO/COO severance includes 12-18 months COBRA and full equity vesting upon change of control.
Price Impact
More from KURA